Direkt zum Inhalt
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
DE
FR
EN
PT
NL
NB
DE
IT
Startseite
Company Press Releases
Company press releases
Abonnieren
Filter
Filter
Aktualisieren
Zurücksetzen
Icon After
Datum
Toggle Visibility
Alle
Heute
This week
This month
Custom date range
From
To
Topic
Toggle Visibility
Acquisition or disposal of the issuer’s own shares
Additional regulated information required to be disclosed under the laws of a Member State
Adjustment of interest rate
Alliances and agreements
Annual financial and audit Reports
Change in Capital
Changes in the rights attaching to the classes of shares or securities
Commercial operations
Commercial results
Corporate life
Dividend
Ex Date
General meeting / Board Meeting
Half yearly financial reports and audit reports/limited reviews
Home Member State
Income
Inside information
Joint venture
Journal / appointments
Legal
Major shareholding notifications
Mandatory notification of trade primary insiders
Meetings / events
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Non-regulatory press releases
Other financial transaction
Other subject
Payments to governments
Polls / Surveys
Products and services
Prospectus / admission document
Rating
Sales
Share history
Share introduction and issues
Takeover bids
Total number of voting rights and capital
Trends / Analyses
Provider
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Displaying 201 - 221 of 221 results
Released
Company
Title
Industry
Topic
26 Jan 2022
18:00 CET
MAAT PHARMA
MaaT Pharma Announces Ordinary and Extraordinary Shareholders’ General Meeting on March 3, 2022, and the Availability of Preparatory Documents
20103010 Biotechnology
General meeting / Board Meeting
24 Jan 2022
07:30 CET
MAAT PHARMA
MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study
20103010 Biotechnology
Other subject
24 Jan 2022
07:30 CET
MAAT PHARMA
MaaT Pharma annonce des résultats intermédiaires positifs de colonisation pour MaaT033, sa formulation orale, permettant de conclure plus rapidement l’essai CIMON de Phase 1b
20103010 Biotechnology
Other subject
17 Jan 2022
18:00 CET
MAAT PHARMA
MaaT Pharma Provides Business Objectives and Expected Milestones for 2022
20103010 Biotechnology
Other subject
17 Jan 2022
18:00 CET
MAAT PHARMA
MaaT Pharma présente ses objectifs et les prochaines étapes de développement pour l’année 2022
20103010 Biotechnology
Other subject
13 Jan 2022
19:00 CET
MAAT PHARMA
MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas
20103010 Biotechnology
New
13 Jan 2022
19:00 CET
MAAT PHARMA
MaaT Pharma annonce l’initiation de la couverture de son titre par KBC Securities, Kempen et Portzamparc / Groupe BNP Paribas
20103010 Biotechnology
New
03 Jan 2022
19:00 CET
MAAT PHARMA
MaaT Pharma to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
20103010 Biotechnology
Other subject
03 Jan 2022
19:00 CET
MAAT PHARMA
MaaT Pharma annonce sa participation à la conférence virtuelle H.C. Wainwright BioConnect 2022
20103010 Biotechnology
Other subject
03 Jan 2022
18:00 CET
MAAT PHARMA
MaaT Pharma S.A. : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
20103010 Biotechnology
Other financial transaction
11 Dec 2021
21:00 CET
MAAT PHARMA
MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting
20103010 Biotechnology
Other subject
11 Dec 2021
21:00 CET
MAAT PHARMA
MaaT Pharma présente, à l’occasion de la 63ème rencontre annuelle de l’ASH, des résultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l’hôte aigüe traités avec MaaT013
20103010 Biotechnology
Other subject
06 Dec 2021
07:30 CET
MAAT PHARMA
MaaT Pharma Announces the Partial Exercise of the Over-Allotment Option and the Total Size of the Offering at Approximately €35.7m
20103010 Biotechnology
Other financial transaction
06 Dec 2021
07:30 CET
MAAT PHARMA
MaaT Pharma annonce l’exercice partiel de l’option de surallocation et le montant définitif de l’offre porté à environ 35,7 M€
20103010 Biotechnology
Other financial transaction
02 Dec 2021
09:23 CET
MAAT PHARMA
MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013
20103010 Biotechnology
Meetings / events
01 Dec 2021
19:30 CET
MAAT PHARMA
MaaT Pharma organisera une réunion d'information à destination des investisseurs après la présentation de résultats complémentaires de MaaT013 lors de la conférence de l'ASH
20103010 Biotechnology
Meetings / events
25 Nov 2021
20:35 CET
MAAT PHARMA
MaaT Pharma S.A. : Opérations de stabilisation
20103010 Biotechnology
Other financial transaction
09 Nov 2021
18:11 CET
MAAT PHARMA
MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
20103010 Biotechnology
Other subject
09 Nov 2021
18:11 CET
MAAT PHARMA
MaaT Pharma présentera des résultats complémentaires de l’essai clinique de phase II et du programme d’accès compassionnel de MaaT013 lors d’une présentation orale aux 63ème Rencontres de l’American Society of Hematology
20103010 Biotechnology
Other subject
03 Nov 2021
20:05 CET
MAAT PHARMA
MaaT Pharma announces successful Initial Public Offering on the regulated market of Euronext Paris
20103010 Biotechnology
Other subject
03 Nov 2021
20:05 CET
MAAT PHARMA
MaaT Pharma annonce le succès de son introduction en Bourse sur le marché réglementé d’Euronext à Paris
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Seitennummerierung
«
« First
‹
‹‹
3
4
5
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
your account
section or
create an account
.
Home
Markets
Amsterdam
Cash Products
Stocks
AEX index Stocks
AEX ESG Stocks
Indices
Funds
Bonds
ETFs
Structured products
Derivative products
Index options
Index futures
Stock options
Dividend derivatives
Stock futures
Quote Vendor Codes
Company regulated news
Latest
Archive
Brussels
Cash products
Stocks
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indices
Bonds
ETFs
Structured Products
Derivative products
Index futures
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisbon
Cash Products
Stocks
Euronext regulated
Euronext Access
PSI Stocks
Indices
Bonds
Derivative products
Index futures
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Cash Products
Stocks
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX stocks
OBX ESG Stocks
OSEBX stocks
OSEFX Stocks
Seafood Stocks
Shipping Stocks
Equity indices
Bonds
Oslo Børs
Nordic Alternative Bond Market
Bond indices
ETFs
Funds
Derivatives
Derivative products
Quote Vendor Codes
Company regulated news
Latest
Archive
Financial calendars
Primary insiders
Paris
Cash Products
Stocks
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indices
Bonds
ETFs
Structured products
Derivative products
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Aktien
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Company regulated news
Latest
Archive
IPOs
All IPOs
Listing sponsors
Euronext Tech Leaders
Family business
Indices
Directory
ESG indices
Indices documents
Indices news
Index consultations
Contact Euronext indices
ETFs
Directory
ESG ETFs
Funds
Directory
ESG Funds
Oslo Mutual Funds
Fixed Income
ESG Bonds
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Structured Products
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Equity Derivatives
Index Futures
Index Options
Stock Options
Stock Futures
Dividend Derivatives
ETF Options
Contracts specifications
Tick Sizes
Wholesale Trading
Quote vendor codes
Rohstoffe
Kurse
Kurse überblick
Weizen Future
Rapssaat Future
Mais Future
European Durum Wheat Futures
Weizen Optionen
Rapssaat Optionen
Mais Optionen
Handelskalender
Lieferung
Wholesale Trading
Commitments of Traders (CoT) report
Spezifikationen
Vendor Codes
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Resources
Statistics & reports
Quality of execution
Trading hours & Holidays
Contract specifications
Quote vendor codes
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Market events
Suspended instruments
Stressed Market Conditions
Breach of Double Cap limits
Exceptional Market Conditions
Miscellaneous short messages
Market status
Members list
Issuers compliance
Where to find